Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126 is registered in ClinicalTrials.gov with Ellipses Pharma as lead sponsor.

NCT NCT05573126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05573126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Lead sponsor
Ellipses Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 11, 2023
Completion date
February 29, 2028
Enrollment
95 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive her-2 negative breast cancer, hormone receptor-positive breast cancer, metastatic breast cancer